Micromet, Inc. (NASDAQ:MITI)
| CAPS Rating |
|
|---|---|
| Open | $10.96 |
| Previous Close | $10.97 |
| Daily Range | $10.95 - $10.96 |
| 52-Week Range | $4.13 - $10.99 |
| Market Cap | $1.01B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 2,141,922 |
| Average Daily Volume | 0 |
MITI
VS S&P 500 (SPY)
How do you think MITI will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MITI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MITI News and Commentary
- Amgen Upped to Outperform - Analyst Blog – NASDAQ
- Has Amgen Become the Perfect Stock? – The Motley Fool
- The Week's Top Stock Gainers – The Motley Fool
- 2 Biotech Acquisitions in 1 Day! Let's Throw a Party – The Motley Fool
- UPDATE: Amgen 4Q Profit Falls 9% On Tax Impacts, Charges – SmartMoney
- Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies – Minyanville
- CORRECT: Amgen To Buy Micromet For $1.16 Billion To Boost Cancer Pipeline – SmartMoney
- Amgen To Buy Biotech Micromet For $1.16 Billion To Boost Oncology Platform – SmartMoney
- 2 Positive Signs for Micromet – The Motley Fool
- This Week's 5 Smartest Stock Moves – The Motley Fool
- Whoa! What Just Happened to My Stock? – The Motley Fool
- 5 Biotechs Posting Big Gains – The Motley Fool
- Micromet Maxes Out These 2 Metrics – The Motley Fool
- Make Money in Health-Care Companies the Easy Way – The Motley Fool
- These Cold Stocks Are Heating Up – The Motley Fool
- Vical Transplants Some Firepower – The Motley Fool
- That's One Expensive BiTE – The Motley Fool
- Micromet Strikes Cancer Research Deal With Amgen – SmartMoney
- Bullish Biotech: 5 Biotech Firms Making Great Strides – The Motley Fool
- Great Data! Now Lets See More Than 12 Patients – The Motley Fool
RSS Headlines
Fool UK
